Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announced on September 8, 2026, that its clinical facility in Mexico City has begun recruiting patients for Group Two of its ongoing human clinical study of the Ocumetics Lens, a next-generation accommodating intraocular lens designed to provide clear vision at all distances without glasses.
The Group Two study marks a significant expansion from the safety-focused Group One trial, which concluded in Fall 2025. While Group One primarily assessed safety, Group Two will evaluate both safety and the lens's performance in near and distance vision, a critical step in demonstrating the technology's potential to replace traditional corrective lenses.
The announcement comes as Group One patients approach their 12-month follow-ups, providing the company with valuable longer-term clinical data. According to the company, Group One outcomes “met and exceeded” expectations regarding safety, performance, and handling, offering a strong foundation for the advanced study.
Group Two patients will receive the latest-generation Ocumetics Lens, implanted using an enhanced delivery system. This next-generation technology incorporates design advancements aimed at improving surgical outcomes and visual performance.
“We are extremely excited to begin the process of moving into our larger Group Two study,” said Dean Burns, President and CEO of Ocumetics. “Commencement of this study represents another important milestone in the continued clinical development of the Ocumetics Lens.”
The Mexico City facility, which successfully conducted Group One surgeries in Fall 2025, has started identifying and recruiting eligible patients for the upcoming Fall 2026 surgeries. The company anticipates completing recruitment soon, with surgical dates to be scheduled thereafter.
Burns emphasized the significance of reaching the 12-month milestone for Group One patients, which will provide a substantial body of longer-term clinical data as the company advances the lens. He also highlighted that Group Two introduces the next-generation lens and delivery system, reflecting the company’s commitment to developing a differentiated solution for patients seeking improved vision across a broader range of distances.
The Ocumetics Lens is designed to fit within the eye's natural lens compartment and uses the eye's natural muscle activity to shift focus from distance to near, potentially eliminating the need for glasses or contact lenses. This innovative approach could transform the field of ophthalmology by offering a dynamic alternative to static intraocular lenses currently used in cataract surgery.
The initiation of Group Two recruitment is a critical regulatory and clinical milestone for Ocumetics, moving the product closer to potential commercialization. Successful completion of this study could position the company as a leader in accommodating intraocular lens technology, addressing a significant unmet need in the global vision correction market.
Investors and industry observers will be watching closely as the company releases 12-month data from Group One and proceeds with Group Two surgeries, which are expected to provide pivotal evidence of the lens's safety and effectiveness.
